World Orphan Drug Summit 2011

Orphan drug development: An opportunity not to be missed…
With lower clinical development costs, a growing global market and booming investment levels, orphan drugs are a lot more attractive to large pharma nowadays.

Of course, it’s not as simple as that. Greater investment levels don’t always lead to greater returns. And while it’s true that orphan drugs present a compelling opportunity for industry (and patients), it’s a much more complex picture, fraught with challenges and hurdles to overcome.

The 2nd World Orphan Drug Summit will bring together a great cocktail of industry leaders from pharma/biotech companies, patient advocacy groups, regulators, investors and insurance companies to shares approaches, challenges and successes in orphan drug development. Take back the information and contacts you need to ensure that your orphan drug activities are fulfilling their potential.